Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: Implications for schizophrenia treatment

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 3, 1999, Pages 9-15

  Neumann, Peter J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; MENTAL HEALTH CARE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA;

ADVERTISING; ANTIPSYCHOTIC AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; MANAGED CARE PROGRAMS; PEER REVIEW; PERIODICALS; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032970255     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Elixhauser A, Luce BR, Taylor WR, et al. Health care CEA/CBA: an update on the growth and composition of the literature. MedCare 1993;31: JS1-JS11
2. Elixhauser A, Halpern M, Schmier J, et al. Health Care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 1998;36:MS1-MS9
3. Andrews G. The cost of schizophrenia revisited. Schizophr Bull 1991;17 (3):389-394
4. Beecham J, Knapp M, Fenyo A. Costs, needs, and outcomes. Schizophr Bull 1991;17(3):427-439
5. Capri S. Methods for evaluation of the direct and indirect costs of long-term schizophrenia. Acta Psychiatr Scand 1994;89(suppl 382):80-83
6. Clarke RE. Family costs associated with severe mental illness and substance use. Hosp Community Psychiatry 1994;45:808-813
7. Clarke RE, Drake RE. Expenditures of time and money by families of people with severe mental illness and substance abuse disorders. Community Ment Health J 1994;30:145-163
8. Cuffel BJ, Jeste DV, Halpain M, et al. Treatment costs and use of community mental health services for schizophrenia by age cohorts. Am J Psychiatry 1996;153:870-876
9. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165(suppl 25):18-21
10. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990;14:522-525
11. Dickey B, Norman S-L T, Norton EC, et al. Managing the care of schizophrenia: lessons from a 4-year Massachusetts Medicaid study. Arch Gen Psychiatry 1996;53:945-952
12. Evers SM, Ament AJ. Costs of schizophrenia in the Netherlands. Schizophr Bull 1995;21(1):141-153
13. Knapp M, Kavanagh S. Economic outcomes and cost in the treatment of schizophrenia. Clin Ther 1997;19:128-138
14. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997;19:1470-1445
15. McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull 1991;17(3):375-388
16. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Rep 1991; 106:280-292
17. Rosenheck R, Neale M, Leaf P, et al. Multisite experimental cost study of intensive psychiatric community care. Schizophr Bull 1995;21(1):129-140
18. Rupp A, Keith SJ. The costs of schizophrenia. Psychiatr Clin North Am 1993;16:413-423
19. Salize HJ, Rossler W. The cost of comprehensive care of people with schizophrenia living in the community: a cost evaluation from a German catchment area. Br J Psychiatry 1996;169:42-18
20. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr Res 1995;17:1-3
21. Steinwachs DM, Kasper JD, Skinner EA. Patterns of use and costs among severely mentally ill people. Health Aff 1992;11:178-185
22. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994;39(suppl 2):65S-69S
23. Weiden PJ, Olfsor M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
24. Wells KB, Astrachan BM, Tischler GL, et al. Issues and approaches in evaluating managed mental health care. Milbank Q 1995;73:57-73
25. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995;40(suppl 2):60S-67S
26. Wyatt RJ, Clark KP. Calculating the cost of schizophrenia. Psychiatr Ann 1987;17:586-591
27. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926
28. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996;11:288-299
29. Aronson SM. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139-147
30. Bond GR, Miller LD, Krumwied RD, et al. Assertive case management in 3 CMHCs: a controlled study. Hosp Community Psychiatry 1988;39: 411-418
31. Essock SM, Hargreaves WA, Covell NH, et al. Antipsychotics in research and clinical settings. Psychopharmacol Bull 1996;32:683-697
32. Glazer WM, Ereshefsky L. A pharmacoceonomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-345
33. Goldberg D. Cost-effectiveness studies in the evaluation of mental health services in the community: current knowledge and unsolved problems. Int Clin Psychopharmacol 1995;9:29-34
34. Goldberg D. Cost-effectiveness studies in the treatment of schizophrenia: a review. Schizophr Bull 1991;17(3):453-459
35. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9):66-76
36. Jerrell JM, Hu T-W Cost-effectiveness of intensive clinical and case management compared with an existing system of care. Inquiry 1989;26: 224-234
37. Krupnick JL, Pincus HA. The cost-effectiveness of psychotherapy: a plan for research. Am J Psychiatry 1992;149:1295-1305
38. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412
39. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(9, suppl B):161-165
40. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
41. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-264
42. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-815
43. Cost-Effectiveness in Health and Medicine. Oxford, England: Oxford University Press; 1996
44. Office of Technology Assessment. Identifying Health Technologies That Work: Searching for Evidence. Washington, DC: Office of Technology Assessment; 1998
45. Udvarhelyi IS, Colditz GA, Rai A. Cost effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992;116:238-244
46. Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 1997;17: 402-408
47. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993;25:113-18
48. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258
49. Neumann PJ, Hermann RC, Weinstein MC, et al. Measuring QALYs in dementia. In: Winblad B, Wimo A, Jonsson B, et al. eds. Health Economics of Dementia. Sussex, England: John Wiley & Sons; 1998:359-370
50. Henry D. Economic analysis as an aid to subsidization decision: the development of Australian guidelines for pharmaceuticals. PharmacoEconomics 1992;1:54-67
51. Ministry of Health, Drug Programs Branch, Toronto, Canada. Memorandum Subject: Status Report on Ontario's Draft Guidelines for Economic Analysis of Drugs, May 7, 1992. Toronto, Canada: Ministry of Health, Drug Programs Branch; 1998
52. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers, and psychiatrists. Int Clin Psychopharmacol 1996;11:101-108
53. Torrance GW, Feeny DH, Furlong WJ, et al. Multi-attribute preference functions for a comprehensive health status classification systems: Health Utilities Index Mark 2. Med Care 1996;24:702-722
54. Lax J, Moench E. Pharmacoeconomics and managed care: understanding the issues, concerns, and the environment. Presented at the United States Food and Drug Administration Hearing "Pharmaceutical Marketing and Information Exchange in Managed Care Environments"; October 19, 1995; Silver Spring, Md: 9
55. Zellmer W. Comments of the American Society of Health-System Pharmacists. Presented at the United States Food and Drug Administration Hearing "Pharmaceutical Marketing and Information Exchange in Managed Care Environments"; October 19, 1995; Silver Spring, Md: 4-11
56. Drummond M, Cooke J, Walley T, et al. Economic evaluation in health care decision making. Soc Sci Med 1997;45:653-675
57. Luce BR, Lyles AC, Rentz AM. The view from managed care pharmacy. Health Affairs 1996;4:168-176
58. Steiner C, Powe NR, Anderson GF, et al. The review process used by U.S. health care plans to evaluate new medical technology for coverage. J Gen Intern Med 1996;11:294-302
59. Steiner C, Powe NR, Anderson GF. Coverage decisions for medical technology by managed care: relationship to organizational and physician payment characteristics. Am J Managed Care 1996;2:1321-1331
60. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost-containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997;45:525-533
61. Neumann PJ. Paying the piper for pharmacoeconomic studies. Med Decis Making 1998;18(suppl):S23-S26
62. Neumann PJ, Zinner DE, Paltiel AD. The FDA and regulation of cost-effectiveness claims. Health Aff 1996;15(3):54-71
63. Draft Guidelines: Principles for the Review of Pharmacoeconomic Promotion. Washington, DC: US Food and Drug Administration, Division of Drug Marketing, Advertising, and Communication; 1995
64. Food and Drug Administration Modernization Act of 1997. Washington, DC: US Food and Drug Administration; 1997. Publication 105-115
65. US Congress. Conference committee report on language regarding the use of health economic information amending section 502(a), 21 USC 352(a), of the Federal Food, Drug, and Cosmetic Act; 1997